APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dermatological Non-Steroidal Anti-Inflammatory Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Outlook and Growth Opportunities 2026

Report ID 173983520429 December 2025193 pages

Choose your research edition.

Industry ResearchDermatological Non-Steroidal Anti-Inflammatory Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Dermatological Non-Steroidal Anti-Inflammatory Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dermatological Non-Steroidal Anti-Inflammatory Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dermatological Non-Steroidal Anti-Inflammatory Drugs market include LEAD CHEMICAL, Merck KGaA, Verona Pharma, Arcutis, GlaxoSmithKline PLc, Huadong Medicine, Pfizer Inc., Roche and MSD, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatological Non-Steroidal Anti-Inflammatory Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatological Non-Steroidal Anti-Inflammatory Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Company

LEAD CHEMICAL

Merck KGaA

Verona Pharma

Arcutis

GlaxoSmithKline PLc

Huadong Medicine

Pfizer Inc.

Roche

MSD

Genzyme Co.

Shapuaisi

Sato Pharmaceutical

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Type

Ketotifen

Ketoconazole

Phthalin Butan

Tacrolimus

Prednisone

Loratadine

Cyclosporine A

Others

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Application

Hospital

Clinic

Others

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dermatological Non-Steroidal Anti-Inflammatory Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dermatological Non-Steroidal Anti-Inflammatory Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dermatological Non-Steroidal Anti-Inflammatory Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Dermatological Non-Steroidal Anti-Inflammatory Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatological Non-Steroidal Anti-Inflammatory Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Non-Steroidal Anti-Inflammatory Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatological Non-Steroidal Anti-Inflammatory Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatological Non-Steroidal Anti-Inflammatory Drugs industry.

Chapter 3: Detailed analysis of Dermatological Non-Steroidal Anti-Inflammatory Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Trends Table 2. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Drivers Table 3. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Opportunities and Challenges Table 4. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Restraints Table 5. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Company (2021-2026) Table 7. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Company (Units) & (2021-2026) Table 8. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company, Product Type & Application Table 13. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ketotifen Table 18. Significant Companies of Ketoconazole Table 19. Significant Companies of Phthalin Butan Table 20. Significant Companies of Tacrolimus Table 21. Significant Companies of Prednisone Table 22. Significant Companies of Loratadine Table 23. Significant Companies of Cyclosporine A Table 24. Significant Companies of Others Table 25. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 26. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2021-2026) & (Units) Table 27. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2027-2032) & (Units) Table 28. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Type (2021-2026) Table 29. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Type (2027-2032) Table 30. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type (2021-2026) Table 34. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Hospital Table 36. Significant Companies of Clinic Table 37. Significant Companies of Others Table 38. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 39. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2021-2026) & (Units) Table 40. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2027-2032) & (Units) Table 41. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Application (2021-2026) Table 42. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Application (2027-2032) Table 43. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application (2021-2026) Table 47. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application (2027-2032) Table 48. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 49. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2021-2026) & (Units) Table 50. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Region (2021-2026) Table 51. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2027-2032) & (Units) Table 52. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Region (2027-2032) Table 53. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Region (2021-2026) Table 56. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Region (2027-2032) Table 58. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 61. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026) & (Units) Table 63. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2021-2026) Table 64. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032) & (Units) Table 65. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2027-2032) Table 66. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Market Share by Country (2021-2026) Table 68. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Market Share by Country (2027-2032) Table 70. LEAD CHEMICAL Company Information Table 71. LEAD CHEMICAL Business Overview Table 72. LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 74. LEAD CHEMICAL Recent Development Table 75. Merck KGaA Company Information Table 76. Merck KGaA Business Overview Table 77. Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 79. Merck KGaA Recent Development Table 80. Verona Pharma Company Information Table 81. Verona Pharma Business Overview Table 82. Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 84. Verona Pharma Recent Development Table 85. Arcutis Company Information Table 86. Arcutis Business Overview Table 87. Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 89. Arcutis Recent Development Table 90. GlaxoSmithKline PLc Company Information Table 91. GlaxoSmithKline PLc Business Overview Table 92. GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 94. GlaxoSmithKline PLc Recent Development Table 95. Huadong Medicine Company Information Table 96. Huadong Medicine Business Overview Table 97. Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 99. Huadong Medicine Recent Development Table 100. Pfizer Inc. Company Information Table 101. Pfizer Inc. Business Overview Table 102. Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 104. Pfizer Inc. Recent Development Table 105. Roche Company Information Table 106. Roche Business Overview Table 107. Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 109. Roche Recent Development Table 110. MSD Company Information Table 111. MSD Business Overview Table 112. MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 114. MSD Recent Development Table 115. Genzyme Co. Company Information Table 116. Genzyme Co. Business Overview Table 117. Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 119. Genzyme Co. Recent Development Table 120. Shapuaisi Company Information Table 121. Shapuaisi Business Overview Table 122. Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 124. Shapuaisi Recent Development Table 125. Sato Pharmaceutical Company Information Table 126. Sato Pharmaceutical Business Overview Table 127. Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 129. Sato Pharmaceutical Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Dermatological Non-Steroidal Anti-Inflammatory Drugs Distributors List Table 133. Dermatological Non-Steroidal Anti-Inflammatory Drugs Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Image Figure 2. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (2021-2032) & (Units) Figure 5. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ketotifen Image Figure 10. Ketoconazole Image Figure 11. Phthalin Butan Image Figure 12. Tacrolimus Image Figure 13. Prednisone Image Figure 14. Loratadine Image Figure 15. Cyclosporine A Image Figure 16. Others Image Figure 17. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 18. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Type (2021-2032) Figure 20. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Clinic Image Figure 25. Others Image Figure 26. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 27. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Application (2021-2032) Figure 29. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application (2021-2032) Figure 32. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 33. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Dermatological Non-Steroidal Anti-Inflammatory Drugs Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Ketotifen
  • Ketoconazole
  • Phthalin Butan
  • Tacrolimus
  • Prednisone
  • Loratadine
  • Cyclosporine A
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • LEAD CHEMICAL
  • Merck KGaA
  • Verona Pharma
  • Arcutis
  • GlaxoSmithKline PLc
  • Huadong Medicine
  • Pfizer Inc.
  • Roche
  • MSD
  • Genzyme Co.
  • Shapuaisi
  • Sato Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Dynamics
  1. 2.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Trends
  2. 2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Drivers
  3. 2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Opportunities and Challenges
  4. 2.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Restraints
3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Company
  1. 3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Ranking (2024-2026)
  6. 3.6 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Product Type and Application
  8. 3.8 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dermatological Non-Steroidal Anti-Inflammatory Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Type
  1. 4.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Type Introduction
  2. 4.1.1 Ketotifen
  3. 4.1.2 Ketoconazole
  4. 4.1.3 Phthalin Butan
  5. 4.1.4 Tacrolimus
  6. 4.1.5 Prednisone
  7. 4.1.6 Loratadine
  8. 4.1.7 Cyclosporine A
  9. 4.1.8 Others
  10. 4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type
  11. 4.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type
  15. 4.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2021-2032)
  17. 4.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type (2021-2032)
5 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Application
  1. 5.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application
  6. 5.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application
  10. 5.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application (2021-2032)
6 Dermatological Non-Steroidal Anti-Inflammatory Drugs Regional Sales and Value Analysis
  1. 6.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2027-2032)
  5. 6.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2025 VS 2032
7 Dermatological Non-Steroidal Anti-Inflammatory Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032)
  6. 7.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 LEAD CHEMICAL
  2. 8.1.1 LEAD CHEMICAL Company Information
  3. 8.1.2 LEAD CHEMICAL Business Overview
  4. 8.1.3 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  6. 8.1.5 LEAD CHEMICAL Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Verona Pharma
  14. 8.3.1 Verona Pharma Company Information
  15. 8.3.2 Verona Pharma Business Overview
  16. 8.3.3 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  18. 8.3.5 Verona Pharma Recent Developments
  19. 8.4 Arcutis
  20. 8.4.1 Arcutis Company Information
  21. 8.4.2 Arcutis Business Overview
  22. 8.4.3 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  24. 8.4.5 Arcutis Recent Developments
  25. 8.5 GlaxoSmithKline PLc
  26. 8.5.1 GlaxoSmithKline PLc Company Information
  27. 8.5.2 GlaxoSmithKline PLc Business Overview
  28. 8.5.3 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline PLc Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Pfizer Inc.
  38. 8.7.1 Pfizer Inc. Company Information
  39. 8.7.2 Pfizer Inc. Business Overview
  40. 8.7.3 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  42. 8.7.5 Pfizer Inc. Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 MSD
  50. 8.9.1 MSD Company Information
  51. 8.9.2 MSD Business Overview
  52. 8.9.3 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  54. 8.9.5 MSD Recent Developments
  55. 8.10 Genzyme Co.
  56. 8.10.1 Genzyme Co. Company Information
  57. 8.10.2 Genzyme Co. Business Overview
  58. 8.10.3 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  60. 8.10.5 Genzyme Co. Recent Developments
  61. 8.11 Shapuaisi
  62. 8.11.1 Shapuaisi Company Information
  63. 8.11.2 Shapuaisi Business Overview
  64. 8.11.3 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  66. 8.11.5 Shapuaisi Recent Developments
  67. 8.12 Sato Pharmaceutical
  68. 8.12.1 Sato Pharmaceutical Company Information
  69. 8.12.2 Sato Pharmaceutical Business Overview
  70. 8.12.3 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  72. 8.12.5 Sato Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Value Chain Analysis
  2. 9.1.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Mode & Process
  6. 9.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Distributors
  9. 9.2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst